Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2018 Aug 12. pii: jnnp-2018-318261. doi: 10.1136/jnnp-2018-318261. [Epub ahead of print]

PMID:
30100552
2.

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnes P, Mauri C, Jury EC; ABIRISK Consortium.

JCI Insight. 2018 Jun 7;3(11). pii: 99274. doi: 10.1172/jci.insight.99274. [Epub ahead of print]

3.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061
4.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

5.

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec.

6.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
7.

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.

Warnke C, Graf J, Hartung HP.

Mult Scler. 2017 Aug;23(9):1176-1178. doi: 10.1177/1352458517720045. No abstract available.

PMID:
28749310
8.

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C.

Front Neurol. 2017 Jul 6;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017.

9.

[Weaning Unit of the University Medicine Greifswald - Institutional Structure and Weaning Results from Prolonged Ventilation over 10 Years].

Müller-Heinrich A, Warnke C, Heine A, Bollmann T, Boesche M, Schäper C, Stubbe B, Friesecke S, Felix SB, Gläser S, Obst A, Ewert R.

Pneumologie. 2017 Aug;71(8):514-524. doi: 10.1055/s-0043-103094. Epub 2017 May 15. German.

PMID:
28505685
10.

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1092-1094. doi: 10.1136/jnnp-2016-315298. Epub 2017 May 10. No abstract available.

PMID:
28490505
11.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

Warnke C, Hartung HP.

Mult Scler. 2017 Jun;23(7):920-922. doi: 10.1177/1352458517705480. Epub 2017 May 8. No abstract available.

PMID:
28481191
12.

Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension.

Ewert R, Richter MJ, Steringer-Mascherbauer R, Grünig E, Lange TJ, Opitz CF, Warnke C, Ghofrani HA.

Clin Res Cardiol. 2017 Oct;106(10):776-783. doi: 10.1007/s00392-017-1114-1. Epub 2017 Apr 20.

PMID:
28429083
13.

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.

Wattjes MP, Warnke C.

Mult Scler. 2017 May;23(6):770-771. doi: 10.1177/1352458516685170. Epub 2017 Mar 1. No abstract available.

PMID:
28287040
14.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

15.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R.

Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879. Review.

16.

[Lung Health Data of the Study of Health in Pomerania - a Review of Samples, Methods and First Results].

Ewert R, Ittermann T, Bollmann T, Spielhagen T, Dörr M, Schäper C, Warnke C, Obst A, Friedrich N, Felix SB, Markus MR, Piontek M, Penzel T, Fietze I, Glos M, Stubbe B, Desole S, Kaczmarek S, Schmidt CO, Völzke H, Gläser S.

Pneumologie. 2017 Jan;71(1):17-35. doi: 10.1055/s-0042-117461. Epub 2017 Jan 23. Review. German.

PMID:
28114706
17.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium.

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752. eCollection 2016.

18.

[Progressive multifocal leukoencephalopathy].

Warnke C, Wattjes MP, Adams O, Hartung HP, Martin R, Weber T, Stangel M.

Nervenarzt. 2016 Dec;87(12):1300-1304. Review. German.

PMID:
27730274
19.

Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.

Richter MJ, Ewert R, Warnke C, Gall H, Classen S, Grimminger F, Mayer E, Seeger W, Ghofrani HA.

Clin Res Cardiol. 2017 Mar;106(3):174-182. doi: 10.1007/s00392-016-1037-2. Epub 2016 Sep 26.

PMID:
27670656
20.

Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.

Menge T, Dubey D, Warnke C, Hartung HP, Stüve O.

Expert Rev Neurother. 2016 Oct;16(10):1131-9. doi: 10.1080/14737175.2016.1227242. Epub 2016 Sep 1. Review.

PMID:
27552111
21.

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J, Wattjes MP.

J Neurol. 2016 Oct;263(10):2004-21. doi: 10.1007/s00415-016-8217-x. Epub 2016 Jul 11.

22.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

23.

Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.

Leussink VI, Stettner M, Warnke C, Hartung HP.

J Peripher Nerv Syst. 2016 Jun;21(2):85-7. doi: 10.1111/jns.12169.

PMID:
26968589
24.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
25.

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.

Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, Hartung HP, Malik RA, Kieseier BC.

Ann Clin Transl Neurol. 2015 Dec 28;3(2):88-100. doi: 10.1002/acn3.275. eCollection 2016 Feb.

26.

PML: The Dark Side of Immunotherapy in Multiple Sclerosis.

Warnke C, Olsson T, Hartung HP.

Trends Pharmacol Sci. 2015 Dec;36(12):799-801. doi: 10.1016/j.tips.2015.09.006. Epub 2015 Oct 21.

PMID:
26497099
27.

Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?

Wattjes MP, Warnke C.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):115. doi: 10.1136/jnnp-2015-311386. Epub 2015 Oct 22. No abstract available.

PMID:
26492928
28.

[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Leussink VI, Warnke C, Tackenberg B, Wiendl H, Kieseier BC.

Nervenarzt. 2015 Apr;86(4):483-90. doi: 10.1007/s00115-015-4287-8. German.

PMID:
25833401
29.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755. Review.

PMID:
25800129
30.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12.

PMID:
25392339
31.

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC.

Neurology. 2014 Dec 2;83(23):2153-7. doi: 10.1212/WNL.0000000000001049. Epub 2014 Oct 31.

PMID:
25361781
32.

[Reference values for arterial oxygen content].

Warnke Ch, Bollmann T, Ittermann T, Gläser S, Koch B, Schäper Ch, Lau K, Felix SB, Ewert R.

Pneumologie. 2014 Dec;68(12):788-92. doi: 10.1055/s-0034-1378089. Epub 2014 Oct 8. German.

33.

Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis.

Warnke C, Adams O, Kieseier B.

JAMA Neurol. 2014 Sep;71(9):1192. doi: 10.1001/jamaneurol.2014.1855. No abstract available.

PMID:
25200545
34.

CD19 as a molecular target in CNS autoimmunity.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V.

Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4. Review.

35.

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.

Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Søndergaard HB, Hillert J; International Multiple Sclerosis Genetics Consortium, Oturai AB, Hemmer B, Kockum I, Olsson T.

PLoS Pathog. 2014 Apr 24;10(4):e1004084. doi: 10.1371/journal.ppat.1004084. eCollection 2014 Apr. Erratum in: PLoS Pathog. 2014 Sep;10(9):e1004430. Hemme, Bernhard [corrected to Hemmer, Bernhard].

36.

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O.

Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8.

37.

Teriflunomide for the treatment of multiple sclerosis.

Warnke C, Stüve O, Kieseier BC.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S90-4. doi: 10.1016/j.clineuro.2013.09.030. Review.

PMID:
24321165
38.

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.

Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.

Neurology. 2013 Oct 15;81(16):1400-8. doi: 10.1212/WNL.0b013e3182a84101. Epub 2013 Sep 18.

PMID:
24049136
39.

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.

Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7.

PMID:
23925765
40.

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Gläser S, Obst A, Koch B, Henkel B, Grieger A, Felix SB, Halank M, Bruch L, Bollmann T, Warnke C, Schäper C, Ewert R.

PLoS One. 2013 Jun 20;8(6):e65643. doi: 10.1371/journal.pone.0065643. Print 2013.

41.

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

Warnke C, Kieseier BC, Hartung HP.

J Neural Transm (Vienna). 2013 Sep;120 Suppl 1:S55-60. doi: 10.1007/s00702-013-1055-4. Epub 2013 Jun 21. Review.

PMID:
23793997
42.

[Teriflunomide for treatment of multiple sclerosis].

Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC.

Nervenarzt. 2013 Jun;84(6):724-31. doi: 10.1007/s00115-013-3779-7. Review. German.

PMID:
23695001
43.

Changes to anti-JCV antibody levels in a Swedish national MS cohort.

Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmén C, Olsson T, Hillert J, Fogdell-Hahn A.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1199-205. doi: 10.1136/jnnp-2012-304332. Epub 2013 Mar 5.

44.

An assay to quantify species-specific anti-JC virus antibody levels in MS patients.

Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O.

Mult Scler. 2013 Aug;19(9):1137-44. doi: 10.1177/1352458513475489. Epub 2013 Feb 6.

PMID:
23388163
45.

Recovery of the T-cell repertoire in CIDP by IV immunoglobulins.

Mausberg AK, Dorok M, Stettner M, Müller M, Hartung HP, Dehmel T, Warnke C, Meyer Zu Hörste G, Kieseier BC.

Neurology. 2013 Jan 15;80(3):296-303. doi: 10.1212/WNL.0b013e31827debad. Epub 2012 Dec 26.

PMID:
23269592
46.

[The Study of Health in Pomerania (SHIP) reference values for cardiopulmonary exercise testing].

Gläser S, Ittermann T, Schäper C, Obst A, Dörr M, Spielhagen T, Felix SB, Völzke H, Bollmann T, Opitz CF, Warnke C, Koch B, Ewert R.

Pneumologie. 2013 Jan;67(1):58-63. doi: 10.1055/s-0032-1325951. Epub 2012 Dec 17. German.

47.

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.

Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC.

Ther Adv Neurol Disord. 2012 Sep;5(5):255-66. doi: 10.1177/1756285612453972.

48.

Anti-JC-virus antibody prevalence in a German MS cohort.

Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC.

Mult Scler. 2012 Jul;18(7):1054-5. doi: 10.1177/1352458511429955. No abstract available.

PMID:
22740609
49.

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.

Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, Cadeddu RP, Weigelt C, Fischer U, Kobbe G, Hartung HP, Adams O, Kieseier BC, Haas R.

Arch Neurol. 2011 Nov;68(11):1428-31. doi: 10.1001/archneurol.2011.238.

PMID:
22084125
50.

[Cannabinoids for symptomatic therapy of multiple sclerosis].

Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC.

Nervenarzt. 2012 Jun;83(6):695-704. doi: 10.1007/s00115-011-3401-9. Review. German.

PMID:
22080198

Supplemental Content

Loading ...
Support Center